AeroFact
Respiratory Distress Syndrome (RDS) in preterm infants
Key Facts
About Aerogen Pharma
Aerogen Pharma is a private, clinical-stage biotech developing inhaled therapeutics for critical care, with a lead Phase 3 program (AeroFact) targeting respiratory distress syndrome (RDS) in preterm infants. The company's strategy involves repurposing proven drug molecules and delivering them via a proprietary, high-performance aerosol delivery system derived from the Aerogen Group's market-leading hospital nebulizer platform. Led by an experienced CEO with a strong track record in inhaled drug development, the company aims to establish a new standard of non-invasive aerosol drug delivery to improve patient outcomes and safety in hospital settings. Its current focus is on addressing a significant unmet need in neonatology while building a pipeline for the broader acute and critical care market.
View full company profile